Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China flag China · Delayed Price · Currency is CNY
25.91
+0.12 (0.47%)
At close: May 9, 2025, 2:57 PM CST
-7.24%
Market Cap 2.61B
Revenue (ttm) 825.15M
Net Income (ttm) 45.38M
Shares Out 101.08M
EPS (ttm) 0.45
PE Ratio 57.11
Forward PE n/a
Dividend 0.18 (0.70%)
Ex-Dividend Date May 23, 2024
Volume 1,833,008
Average Volume 2,723,538
Open 26.00
Previous Close 25.79
Day's Range 25.45 - 26.26
52-Week Range 20.25 - 32.50
Beta 0.61
RSI 49.62
Earnings Date Apr 21, 2025

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd. develops and sells Chinese medicines in China. It offers drugs in the areas of gynecology, pediatrics, respiratory system, and other pharmaceutical fields. The company was founded in 2005 and is based in Chengdu, China. [Read more]

Sector Healthcare
Founded 2005
Employees 1,548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301331
Full Company Profile

Financial Performance

In 2024, Enwei Pharmaceutical's revenue was 812.13 million, an increase of 3.43% compared to the previous year's 785.19 million. Earnings were 37.50 million, a decrease of -56.56%.

Financial Statements

News

There is no news available yet.